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Medication management issues in persons with diabetes (PWD) are well documented. Few 
studies have examined community-dwelling older PWD in primary-care provider (PCP) practice 
setting to determine what medications PCPs prescribe and what patients actually take.  
This secondary analysis, guided by Donabedian’s structure-process-outcome framework, 
examined medication discrepancies (MD) in community-dwelling PWD (n = 142), 65 years of 
age and older, in the PCP setting. The aims were to (1) characterize the sample, (2) characterize 
the discrepancies associated with prescribed medications, and (3) identify potential correlates of 
medication discrepancies. This study used de-identified baseline data (n = 533) from a parent 
study (NIH/NIA AG023129), which examined the utility of cognitive function testing of older 
adults in the PCP setting. The Donabedian structure component included variables for subject 
characteristics such as sociodemographic variables, health information, and neuropsychological 
variables. The process component included data from a comprehensive medication review, 
which generated a complete and accurate list of the subject’s current medications and allowed a 
comparison of the patient-generated list with the provider-generated list present in the subject’s 
medical record.  
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 In 95% of the subjects, MD were present. Among subjects with the same number of 
health problems, those with a higher number of medications were more likely to exhibit MD 
compared to the subjects with a lower number of medications. Among patients with the same 
number of medications, those who had a higher number of health problems were less likely to 
have a MD compared to the subjects with fewer health problems.  
Polypharmacy and the number of health problems were the most significant correlates of 
a medication discrepancy. While not significant, a trend was observed for diminished cognitive 
function and the presence of a MD (p = 0.056). Despite a high MMSE mean score (27.9 ± 1.9) 
and positive correlations with neuropsychological scores, mild cognitive impairment was 
discovered in 44% of the sample—and four or more depressive symptoms in 69.72% of the 
sample.  
The pervasiveness of medication discrepancies and health problems in a population of 
PWD at risk for cognitive impairment and depressive symptoms has significant health care 
implications that deserve further study.  
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 1.0  INTRODUCTION 
1.1 STATEMENT OF THE PROBLEM 
The value of pharmacologic therapy to achieve and maintain diabetes mellitus (DM) control has 
been clearly established (Diabetes Prevention Research Group, 2002; Buchanan, T.A., Xiang, 
A.H., Peters, R.K., et al 2002; Chiasson, J.L., Josse, R.G., Gomis, R., et al, 2002). Yet, the ability 
to adequately manage DM has remained elusive and control of DM has remained suboptimal in 
the United States (Stratton et al., 2000). A direct relationship between adherence and glycemic 
control has been documented (Asche, LaFleur, & Conner, 2011; Rozenfeld, Hunt, Plauschinat, & 
Wong, 2008); the World Health Organization (WHO) declared adherence to be the cornerstone 
of metabolic control (World Health Organization, 2003).  Medication adherence is defined as 
taking 80 to 120% of the medication prescribed (Avorn et al., 1998; Hope, Wu, Tu, Young, & 
Murray, 2004; Monane et al., 1996; Sackett et al., 1975). Yet, in a review article, Rubin (2005) 
reports that more than 20 studies found that adherence to oral medication for type 2 diabetes 
mellitus (T2DM) ranged from 65% to 85%.  Medication discrepancies (discordance between the 
prescribed regimen and the medications actually taken each day) further limited treatment 
efficacy (Bedell et al., 2000; Grant, Devita, Singer, & Meigs, 2003b; Wagner & Hogan, 1996; 
Yang, Tomlinson, & Naglie, 2001), hence negatively affecting glycemic control.  
Elderly DM patients have often required multiple medications to treat DM and associated 
comorbidities (Bailey & Kodack, 2011). In a review of DM medication adherence, Odegard and 
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 Capoccia (2007) reported the mean number of medications ranged from 4.1 to 10.2 and the 
number of medications increased with the number of comorbidities. In a large (n = 30,000) study 
of adults 65 years of age and older, Field et al. (2007) corroborated this finding and reported that 
adverse drug events (ADEs) due to patient-generated errors was associated with polypharmacy 
and identified patient-generated medication errors most often involve hypoglycemic medications 
(28.7%) and led to 129 ADEs. Factors identified within the DM patient population have 
increased the complexity of therapeutic regimens, thus placing patients at greater risk for 
medication errors including adverse drug reactions, drug-drug interactions, and non-adherence. 
Prevention of medication errors was the impetus behind the push for medication 
reconciliation which was championed by the Institute of Medicine and identified as a prominent 
intervention in the 100,000 Lives Campaign (Berwick, Calkins, McCannon, & Hackbarth, 2006).  
To promote patient safety and decrease medication errors, the medication reconciliation process 
became a vital component of the health care process across all trajectories of care. Medication 
reconciliation is a comprehensive evaluative process for generating a complete and accurate list 
of a patient’s current medications and comparing the patient-generated list to those in the 
provider-generated list within the patient’s medical record.  The intention of medication 
reconciliation was to promote patient safety by identifying errors of omission, duplication, 
incorrect doses or timing, and the potential for ADEs (“Using Medication,” 2006). The 
medication reconciliation process has been shown to be an effective means to reduce the number 
of medication errors (Pronovost et al., 2003; Rogers et al., 2006). Yet, failures in the medication 
reconciliation process have led to medication errors (Santell, 2006).  
Determination of a medication error often has relied on the existence of a single, 
discrepancy free medication list, or gold standard for medications a patient should be taking 
(Coleman, Smith, Raha, & Min, 2005). For patients who received care from more than one 
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 provider, such a list rarely existed (Frei, Huber, Simon, Bonani, & Lüscher, 2009). Unlike 
medication errors in the acute care setting, medication management and medication 
reconciliation processes in the community have not been comprehensively studied. Healthcare 
providers were often not aware of medication changes that occurred during hospitalizations or 
other care transitions (Layson-Wolf & Morgan, 2008). When medication reconciliations were 
conducted at discharge or within 72 hours of discharge from the hospital, at least one medication 
discrepancy was noted in those patients positive for a discrepancy (Coleman et al., 2005; Unroe 
et al., 2010).  Within 72 hours of discharge in community dwelling adults 65 years of age and 
older, approximately 50% of medication discrepancies were categorized as patient-associated 
and the other 50% were categorized as system-associated.  For patients with medication 
discrepancies, 14.3% were re-hospitalized at 30 days compared with 6.1% having no medication 
discrepancy (Coleman et al., 2005).  Studies in the community setting reported medication 
reconciliation discrepancy rates ranging from 30% to 66% (Barat, Andreasen, & Damsgaard, 
2001; Bloom, Frank, Shafir, & Martiquet, 1993; Coleman et al., 2005; Gleason et al., 2004; 
Gonski, Stathers, Freiman, & Smith, 1993; McKinley, Mulhall, & Jackson, 2004; Moore, 
Wisnivesky, Williams, & McGinn, 2003). 
Medication discrepancies identified during the reconciliation process were perceived as a 
source of error, an indicator for potential medication nonadherence, and a risk for potential ADE 
and negative outcomes. Likewise, the discovery of a medication discrepancy may lead to 
corrective actions among patients, and providers, and within the healthcare system to promote 
more positive outcomes than otherwise may have been realized. 
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 1.2  PURPOSE AND AIMS 
The overall purpose of this secondary data analysis was to examine medication discrepancies 
associated with DM in adults 65 years of age and older who were community dwelling primary 
care patients. The specific aims were to (1) characterize the sample of older community dwelling 
patients with DM, (2) characterize the discrepancies associated with prescribed medications, and 
(3) identify potential correlates of medication discrepancies.  The main outcome measure was the 
presence of discrepancies based on the process of comparing provider-recorded medications and 
patient self-reported medications.   
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 2.0  BACKGROUND AND SIGNIFICANCE 
Medication management issues in the treatment of diabetes have been well documented, but less 
is known about the pervasiveness and factors contributing to medication discrepancies associated 
with diabetic patients 65 years of age and older living in the community and utilizing a primary 
care provider. Avedis Donabedian, a physician and health services researcher, recognized the 
importance of evaluating the quality of health care and proposed a direct relationship between 
quality of the care provided and patient safety (Donabedian, 1966). 
2.1 CONCEPTUAL MODEL 
Donabedian (1966) introduced the structure-process-outcome (SPO) conceptual framework;  the 
foundation for modern healthcare quality measurement. He proposed that good structure 
promoted appropriate processes of care and better patient outcomes.  
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Figure 1.  Donabedian Conceptual Framework 
 
Structural categories considered important in assessing the quality of structure are (1) 
client or patient characteristics, (2) provider characteristics, and (3) system characteristics. The 
process component focuses largely on the intervention or treatment process, what is done for the 
patient; it includes interpersonal process factors and technical skill in the delivery of services.  
Interpersonal process refers to the way providers relate to patients. Technical skill refers to the 
specific services used and the way in which providers manage the care, which includes 
continuity of care and its coordination. Outcome is the final component of the framework, and is 
the ultimate test of the effectiveness of healthcare. Outcomes are the endpoints or results of an 
intervention or healthcare practice, such as RN staffing and outcomes of hospital related 
mortality and adverse patient events.  
Donabedian’s (1966) conceptual model, heretofore identified as the SPO model has been 
used by both health services and quality improvement researchers (Romano & Mutter, 2004).    
In health care studies guided by the SPO model, research findings have verified links between 
structural measures and processes and outcomes of care (Mitchell & Shortell, 1997). Health 
services research, guided by the SPO model, typically utilize either process or outcome measures 
6 
 but not all three components of the model. The rationale for choosing one measure over the other 
was due to limitations within the data. Therefore, health services research that utilizes existing 
data sets not only is primarily tailored to either process or outcome measures, but also rarely 
combines both types of measures. Utilization of process measures have been prevalent in quality 
improvement and health policy research (Crombie & Davies, 1998). Process measures have been 
used in intervention studies to assess how providers evaluate and treat patients (Romano & 
Mutter, 2004). Outcome measures, primarily studied by health services researchers, have been 
indicative of end results of care (Crombie & Davies, 1998). Other outcome studies utilizing the 
SPO model have investigated patient assessments of health care (Oropesa, Landale, & Kenkre, 
2002; Westaway, Rheeder, Van Zyl, & Seager, 2003). 
Donabedian's (1966) SPO model presumed high-quality healthcare environment 
indicators were linked to patient safety. Health care researchers used the structure-outcome 
components of the SPO model to investigate patient safety. Adverse events at the patient care 
unit or care team level versus the hospital/system level were investigated as outcome measures to 
evaluate quality.  Those researchers reported positive relationships with quality (Blegen & 
Vaughn, 1998; Naveh, Katz-Navon, & Stern, 2006; Pollack, Koch, & Network, 2003).  Studies 
of quality improvement (QI) that utilized structure-outcome components also found positive 
relationships with quality (Aiken & Sloane, 1997; Aiken, Sloane, & Lake, 1997). Studies of QI 
utilizing structure-process components found no relationship with quality (Gill, Ryan, Morgan, 
& Williams, 2000; Kanse, van der Schaaf, Vrijland, & van Mierlo, 2006) with the exception of 
Brundage et al.,(1999) who found a positive relationship.  Quality improvement studies using 
process-outcome components found positive relationships with quality (Curley, 1998; Glasson et 
al., 2006; Merlani, Garnerin, Diby, Ferring, & Ricou, 2001). 
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 None of the above studies utilized the SPO model or mixed components of the SPO 
model to investigate the process of medication reconciliation with resulting medication 
discrepancies in a primary care setting for persons with diabetes. It remains important to gain 
insight about the influence of structural components (i.e., patient characteristics) on the 
medication reconciliation process and the resulting medication discrepancies. 
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2.2  OPERATIONAL MODEL 
The operational model guiding this study, which addresses patient factors and medication 
reconciliation, is depicted as follows: 
 
 
 
Figure 2. Operationalized Donabedian SPO Model 
 
2.2.1  Structure: Potential factors associated with medication discrepancies  
Medication discrepancies have numerous causes and sources.  The National Council on Patient 
Information and Education (NCPIE) categorized factors that contributed to the medication 
problems as patient-related and medication-related factors, government impediments, as well as 
prescriber and pharmacy related factors (National Council on Patient Information and Education, 
2007).    
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 Independent community dwelling older adults faced multiple challenges when managing 
a complex medication regimen (Ahrens, Feldman, & Frey, 2002; Davis et al., 2006; Kairuz et al., 
2008; Russell et al., 2006).  Researchers identified many factors associated with an increased risk 
of medication errors. Patient characteristics of age, gender, living arrangements, social support, 
physical function, and neuropsychological status were identified as pertinent predictors, which 
contributed to medication discrepancy errors.   
Patient Factors 
Age was consistently cited as a factor related to medication discrepancies (Bedell et al., 2000; 
Gilbert, Luszcz, & Owen, 1993).  Marek (2008) reported that older adults present with decreased 
comprehension of medication instructions and adherence. In a study of individuals aged 75 and 
older, Barat, Andreasen, and Damsgaard (2001) found that knowledge of medication for 
treatment was poor and non-adherence ranged from 20%–70%.   Multiple physiologic and 
metabolic processes, including drug absorption, distribution, metabolism, and excretion of 
medications were affected by aging (Beers, Baran, & Frenia, 2000).  
The 2011 CDC National Diabetes Fact Sheet reported an increasing prevalence of DM in 
the United States from approximately nine percent in 1980 to approximately 20% for those 
above the age of 65 years in 2010; and the prevalence increased with increasing age, to more 
than 11 times that of people younger than 45 years of age as reported in 2010 (Centers for 
Disease Control and Prevention, 2011). The prevalence of DM increased across age groups: men 
aged 65–74 years had an increased prevalence from 9.4% to 23.2%, and over the age of 75 the 
increase was from 7.6% to 23.8% between 1980 and 2010.  Women aged 65–74 years had an 
increased prevalence from 8.9% to 18.6%, and over the age of 75 the increase was from 9.6% to 
17.7% between 1980 and 2010, indicating that males had a higher prevalence of diagnosed DM 
10 
 than females.  Twenty-one percent of new persons with diabetes were diagnosed between the 
ages of 65–79 years but the majority of new diagnoses (63%) occurred between the ages of 40 
and 64, leading to a conclusion that older adults had a longer duration of disease. (Centers for 
Disease Control and Prevention, 2011).  While the prevalence of DM in older males was higher 
than in females, the female gender was predictive of medication discrepancies in the outpatient 
setting (Bedell et al., 2000; Wolff, Starfield, & Anderson, 2002). 
Comorbidities 
Multiple chronic diseases were common in 65% to 80% of the elderly population (Britt, 
Harrison, Miller, & Knox, 2008; Weiss, Boyd, Yu, Wolff, & Leff, 2007; Wolff et al., 2002). 
Almost 75% of adults with diabetes had two or more comorbid conditions which accounted for 
much of the morbidity and mortality in those patients (Halanych et al., 2007; Howard et al., 
2006; Kerr et al., 2007). Caughey et al. (2010) reported a mean of five comorbidities in the 
persons with diabetes over 65 years of age.  A higher disease burden due to comorbidities was 
reported to increase the risk for poorer cognitive functioning (Patrick, Gaskovski, & Rexroth, 
2002; Proctor et al., 2003).  Greater than eight medical comorbidities and a family history of 
dementia was associated with lower cognitive function (Morrow, Snitz, Rodriquez, Huber, & 
Saxton, 2009).  An increased number of comorbid conditions were related to decreased treatment 
prioritization of diabetes in relation to other diseases, and decreased the ability of persons with 
diabetes to self-manage their disease (Halanych et al., 2007; Kerr et al., 2007).  
Polypharmacy 
Associated with comorbidity was the use of multiple medications in the older adult 
(Ciechanowski, Katon, & Russo, 2000; Miksch et al., 2009), and specifically in persons with 
diabetes (Caughey et al., 2010; Good, 2002; Odegard & Capoccia, 2007). In a study of T2DM 
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 and hypertension in 44 primary care clinics, polypharmacy was common with more than one-half 
of patients taking five or more medications (Hunt, Kreiner, & Brody, 2012).  In a study (n = 
18,968) of elderly persons with diabetes, the median number of unique medicines dispensed was 
10 (IQR 7–14) and over 70% of the patients were dispensed five or more unique medications 
(Caughey et al., 2010). This supported the findings of 4.1 to 10.2 medications, proportional to 
the number of comorbidities, in a systematic review of medication adherence in diabetes by 
Odegard & Capoccia (2007) not isolated to elderly adults. Polypharmacy has been associated 
with an increased risk of inappropriate prescribing and adverse drug reactions, resulting in an 
increase in adverse outcomes, such as falls, hospital admissions and mortality. Yet, counter to 
current treatment guidelines, early and aggressive polypharmacy in T2DM patients was 
recommended to modify the disease and aim for tight glycemic control which also would modify 
other outcomes related to comorbidities (Wright, Stonehouse, & Cuddihy, 2010).  
Living Arrangements 
In a systematic literature review spanning the years 1948 to 2001, DiMatteo (2004), found strong 
evidence of a relationship between social support, living arrangements, and patient adherence to 
medical regimens. Greater social support (e.g., family and living arrangements) and enhanced 
medication adherence was related to decreased medication errors (DiMatteo, 2004).  Living 
arrangements were important to the elderly adult due to involvement with managing 
medications. A lack of social support with monitoring may have led to medication errors (Barat 
et al., 2001; Dunbar-Jacob, Bohachick, Mortimer, Sereika, & Foley, 2003).  
Sensory Changes 
Sensory changes have been recognized in older adults.  Auditory and visual impairments can 
interfere with the ability to follow instructions given by healthcare providers.  Visual (Mehuys et 
al., 2012) and hearing impairment (Cárdenas-Valladolid et al., 2010) were both identified as 
12 
 sensory deficits negatively affecting adherence in studies (n = 338 and n = 327, respectively) of 
community dwelling older adults. 
Neuropsychological status 
In the “Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-
MIND)” trial, Cukierman-Yaffe et al. (2009) concluded higher A1C levels were associated with 
lower cognitive function in T2DM individuals with cardiovascular risk factors. Moreover, 
diabetes has been recognized as a potentially modifiable risk factor for cognitive compromise 
(Luchsinger et al., 2011).  Similarly, Tuma (2007) reported that persons with diabetes had an 
increased risk of developing cognitive impairment in comparison to the general population and 
cognitive dysfunction was associated with poorer ability in diabetes self-care and decreased 
adherence to antidiabetic treatments.  Additionally, patients with cognitive decline were reported 
to have increased healthcare utilization as evidenced by an increase in PCP visits (Fowler et al., 
2012).  
The Mini-Mental State Examination (MMSE) was developed as a practical method of 
grading cognitive impairment of elderly individuals in the clinical setting (Folstein, Folstein, & 
McHugh, 1975) and widely used as a screening tool for detecting changes in cognitive skills 
(Tombaugh & McIntyre, 1992). Surveys of health professionals reported the MMSE was the 
most commonly utilized cognitive test used by nine out of 10 specialists (Davey & Jamieson, 
2004; Shulman et al., 2006). The MMSE has been used in clinical trials to measure cognitive 
decline in persons with diabetes (Bruce et al., 2008; Ravona-Springer et al., 2010; Williamson et 
al., 2007). In a study of 396 patients aged 65 years or older with known diabetes mellitus, those 
with MMSE scores less than 23 fared worse on measures of self-care and ability to perform 
activities of daily living (Sinclair, Girling, & Bayer, 2000).  Yet, despite the reports 
13 
 demonstrating the association of diabetes with cognitive decline, cognitive assessment has not 
been consistently performed as part of the routine evaluation and follow-up of patients in the 
primary care setting (Ganguli et al., 2004).  
Memory Related Issues 
In 1993, the incidence of healthy, nondemented older adults over the age of 75 years reporting 
subjective memory complaints (SMC) was 35–40% (Grut et al., 1993).  SMC is how one 
interprets, feels, or thinks about his/her own memory and the (formal or informal) reporting of 
that memory (Pearman & Storandt, 2004; Ramakers et al., 2009; Siersma, Waldemar, & 
Waldorff, 2013; Wong et al., 2006).  Subjective memory complaints in the absence of psychiatric 
or neurological disorders have been increasingly reported among healthy older adults (de Groot 
et al., 2001; Metternich, Kosch, Kriston, Härter, & Hüll, 2010), and SMCs were associated with 
a 60% increase in health care utilization cost over a three year period (Waldorff, Siersma, & 
Waldemar, 2009). In a population-based study (n = 2,146), poor psychological well-being, 
depressive symptoms, and hearing impairment were reported to be the strongest predictors of 
SMCs (Benito-León, Mitchell, Vega, & Bermejo-Pareja, 2010). Associations have been found 
between memory complaints and cognitive impairment on testing, even after adjustment for 
depressive symptoms (Waldorff et al., 2009). In a study of 140 participants over the age of 60 
years in a residential facility assessed clinically for dementia, the sensitivity and specificity of 
several instruments were measured using receiver operating characteristic (ROC) analysis 
(Ramlall, Chipps, Bhigjee, & Pillay, 2013).  Subjective Memory Complaint Clinical, MMSE, 
and Clock Drawing Test (CDT) were found to be “moderately accurate” in screening for 
dementia with an area under the curve (AUC) > 0.70. Associations between SMCs and 
14 
 depression and MMSE scores were also reported (Schmand, Jonker, Geerlings, & Lindeboom, 
1997). 
Depressive Symptoms 
The prevalence of depression and health care utilization in single and multiple morbidities was 
investigated in a population-based cohort study (n = 299,912); concurrent diabetes, coronary 
heart disease, and stroke were linked to a high prevalence of depression (men 23%, women 49%) 
(Bhattarai, Charlton, Rudisill, & Gulliford, 2013). Persons with diabetes were reported to be 
twice as likely to have depression (Munshi et al., 2006), and even low levels of depressive 
symptomatology were associated with nonadherence to important aspects of diabetes self-care 
(Gonzalez & Esbitt, 2010; Gonzalez et al., 2007). Persons with diabetes having three to eight 
comorbidities were at particular risk of depression (Caughey et al., 2010). Therefore, depression 
was associated with more diabetic complications, lower medication adherence, and poorer self-
care of diabetes (Lin et al., 2006). 
2.2.2  Process: Medication Reconciliation 
Medication reconciliation was the process designed to improve patient safety by decreasing 
medication errors of omission, commission, duplication, incorrect doses or timing, and adverse 
drug-drug or drug-disease interactions.  During medication reconciliation a list of all medications 
a patient is taking is created and maintained—including drug name, dosage, frequency, and 
route—that list is then used to guide therapy (Institute for Healthcare Improvement, 2011). The 
process of medication reconciliation was a core component of The Institute for Healthcare 
Improvement’s (IHI) 5 Million Lives Campaign. 
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 In 2002, The Joint Commission (TJC) established the National Patient Safety Goals 
(NPSGs) program; the first set of NPSGs was effective January 1, 2003 (The Joint Commission, 
2006).  In July 2004, to promote patient safety and decrease medication errors, TJC announced 
the 2005 National Patient Safety Goal #8 to “accurately and completely reconcile medications 
across the continuum of care” (p. 38). The steps in the process were to (1) develop a list of 
current medications, (2) develop a list of medications to be prescribed, (3) compare the 
medications on the two lists, (4) make clinical decisions based on the comparison, and (5) 
communicate the new list to appropriate caregivers and to the patient (The Joint Commission, 
2006).   
During October 2009, TJC formed focus groups with ambulatory health care, behavioral 
health care, critical access hospitals, hospital, home care, long-term care, and office-based 
surgery customers to discuss the medication reconciliation National Patient Safety Goal (NPSG). 
The groups discussed the components of a medication reconciliation process; the points in the 
care process that needed to be addressed; and the ideal elements for the medication reconciliation 
goal. The NPSG was subsequently revised and the medication reconciliation process was 
streamlined to place a spotlight on critical risk points and became three steps: (1) Verification 
(collection of the medication history); (2) Clarification (ensuring that the medications and doses 
are appropriate); (3) Reconciliation (documentation of changes in the orders). It became effective 
July 1, 2011 (The Joint Commission, 2011).  
A study of patients in four academic, ambulatory primary care internal medicine clinics 
tested interventions to provide performance feedback and training to the health care team, and 
increase patient awareness and participation in the medication reconciliation process. 
Completeness of medication lists improved from 20.4% to 50.4% (p = 0.001). Correctness of 
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 medication lists improved from 23.1% to 37.7% (p = 0.087). Patient participation in the 
medication reconciliation process increased from 13.9% to 33% (p = 0.001). The medication list 
accuracy improved from 11.5% to 29% (p = 0.014) (Nassaralla, Naessens, Chaudhry, Hansen, & 
Scheitel, 2007). Multiple definitions of medication discrepancy were found in the literature. 
According to Tjia (2009), medication discrepancies were unexplained differences among 
documented regimens across different sites of care.  In an outpatient setting, Bedell et al. (2000) 
defined medication discrepancy as “the difference between the list of medications in the medical 
record (referred to as recorded medications) and what a patient actually took, based on 
medication bottles and on self-reports (referred to as reported medications)” (p. 2131). 
Murphy and colleagues (2009) were of the opinion that until medication discrepancies 
could consistently and accurately be identified, the risks of medication errors and ADEs would 
continue. They proposed that the concept of medication discrepancy and the processes used to 
both prevent and correct medication discrepancies were poorly understood and hindered a proper 
medication reconciliation process.  Therefore, when Murphy et al. (2009) conceptualized 
medication discrepancy in the context of patient safety, the initial step in the medication 
reconciliation process was identified as being the critical landmark for identifying the 
discrepancies between two or more medication lists. Further review of the literature revealed 
prescribing issues and patient adherence to regimens as two aspects of discrepancies within the 
context of medication management. 
Multiple studies demonstrated discrepancies from 30% to 94% in what medications were 
ordered by the prescribing provider and the actual medications the older adult was taking (Barat 
et al., 2001; Bedell et al., 2000; Bloom et al., 1993; Coleman et al., 2005; Corbett, Setter, 
Daratha, Neumiller, & Wood, 2010; Gonski et al., 1993; McKinley et al., 2004; Moore et al., 
2003). Corbett et al (2010) investigated a sample of 101 older adults recently discharged from 
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 the hospital who were living at home and identified 69% of the participants as having system-
level discrepancies and 40% with patient-level discrepancies. A meta-analysis by Tam et al. 
(2005) estimated that 27% to 54% of patients suffer at least one unintentional medication 
discrepancy due to medication history errors. 
Providers were often unaware of all prescribed medications their patients were taking 
(Barat et al., 2001; Bonner & Carr, 2002; Fineman & DeFelice, 1992; Torrible & Hogan, 1997), 
particularly when multiple providers were involved due to multiple patient comorbidities. A 
direct relationship was identified between the number of prescribing providers and the presence 
of medication discrepancies (Bedell et al., 2000; Malhotra, Karan, Pandhi, & Jain, 2001; 
Tamblyn, McLeod, Abrahamowicz, & Laprise, 1996; Tulner et al., 2009). Additionally, a direct 
relationship was found between the number of medications and the number and type of 
discrepancies elicited by comparing pharmacy records and a brown bag medication review 
(Caskie, Willis, Warner Schaie, & Zanjani, 2006).   
Medication discrepancies related to providers in acute care settings were categorized as 
intentional and unintentional discrepancies and were used in research involving the classification 
and prediction of errors related to inpatient medication reconciliation (Pippins et al., 2008). 
These researchers reported a prevalence of unintentional medication discrepancies (average of 
1.4 per patient) with potential for patient harm. Most of the medication errors were due to 
omission and the majority of potential ADEs occurred at discharge rather than admission. 
Discrepancies of these types were not distinguished in outpatient or primary care studies 
involving medication reconciliation.   
When a discrepancy existed between the use of a medication and the prescription 
directions, the drug-taking behavior was deemed nonadherent.  Intentional nonadherence was 
investigated in elderly patients (Cooper, Love, & Raffoul, 1982); 90% of nonadherence was 
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 found to be related to underuse; 73% of nonadherence was intentional and was more likely to 
occur in patients who used two or more pharmacies and two or more physicians.  Stack et al. 
(2010) reported intentional nonadherence in community dwelling T2DM patients on oral 
antidiabetic medications and found it to be unrelated to the number of prescribed medications.   
 Grant et al. (2003a) conducted a randomized control trial in persons with diabetes to 
improve adherence and reduce medication discrepancies.  Medical regimen discrepancies were 
identified in 44% of the patients randomized to the intervention arm; 60% of the discrepancies 
were resolved by corrections in the medical record and 7% were resolved by patient corrections. 
Medication discrepancies were reported to be important contributors to adverse drug events 
(ADEs) among hospitalized and recently discharged patients (Cornish et al., 2005; Schnipper et 
al., 2006).  
According to TJC, when medication errors resulted in death or major injury, 63% were 
related communication breakdowns, and approximately half of those would have been avoided 
through effective medication reconciliation. The U.S. Pharmacopeia began to capture types of 
errors involving medication reconciliation failures (CAPSLink, 2005). Early studies reported that 
at least one-half of all patients had at least one potential ADE identified during the reconciliation 
process (Cornish et al., 2005; Gleason et al., 2004; Lau, Florax, Porsius, & De Boer, 2000; 
Rozich et al., 2004). 
The terms medication error, medication discrepancy, potential adverse drug event, 
adverse drug event, and preventable adverse drug event have been used interchangeably in the 
literature. The Institute of Medicine (IOM) in conjunction with the Committee on Data Standards 
for Patient Safety adopted the following definitions as proposed by Bates et al. (1995):  a 
medication error is any error occurring in the medication use process and an adverse drug event 
is any injury attributed to medication error.  Medication error was identified as one of the most 
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 frequent forms of medical error and was associated with significant medical harm (Santell, 
2006).  A medication error can originate at system, provider, and patient levels. It was reported 
that diabetes-related medical errors in outpatient practice were common and costly, with 
approximately 80% of persons with diabetes experiencing at least one error in their diabetes care 
during a year (O'Connor, Sperl-Hillen, & Klein, 2007).   
 Based on the above definition of medication error, a medication discrepancy is an error.  
A subset of patients were identified as being responsible for “patient-related” medication errors 
causing ADEs in a large study of 30,000 Medicare enrollees followed over a 12-month period 
(T. S. Field, K. M. Mazor, B. Briesacher, K. R. Debellis, & J. H. Gurwitz, 2007).  The majority 
of patient errors leading to ADEs (n = 129) occurred in administering the medication (31.8%), 
modifying the medication regimen (41.9%), or not following clinical advice about medication 
use (21.7%).  Possibly, the latter two patient-related errors may have been detected as medication 
discrepancies during a medication reconciliation process, thus potentially avoiding ADEs. 
Patient-related errors in this study most often involved hypoglycemic medications (28.7%), 
followed by cardiovascular medications (21.7%), anticoagulants (18.6%), and diuretics (10.1%) 
(Field et al., 2007).  These findings support other studies linking polypharmacy and 
comorbidities in older adults to increased risk for nonadherence, medication errors, ADEs, and 
increased utilization of healthcare resources due to medication discrepancies.  
Adverse drug events were defined as injuries due to a medication, and potential ADEs 
were defined as medication errors with the potential to cause an injury (Field et al., 2007). 
Adverse drug events were identified as a direct consequence of clinical care and were a key 
focus of the $1 billion federal initiative Partnership for Patients—the goal of which was to 
reduce harm to patients and reduce health care costs by decreasing the number of preventable 
rehospitalizations by 20% by the end of 2013 (Kocher, Emanuel, & DeParle, 2010).  Most 
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 emergency hospitalizations for recognized adverse drug events in older adults resulted from a 
few commonly used medications, 40% of which were antidiabetic medications. Therefore, 
improved management of antidiabetic medications had the potential to significantly reduce 
hospitalizations for ADEs in older adults (Budnitz, Lovegrove, Shehab, & Richards, 2011). In a 
national epidemiologic study, an estimated 265,802 emergency department visits for ADEs 
occurred annually from 2007 through 2009 among adults 65 years of age or older, of which 
37.5% required hospitalization (Budnitz et al., 2011).  Medications commonly implicated in 
emergency hospitalizations for older adults in the United States were insulin and oral 
hypoglycemic agents, ranked second (n = 13,854) and fourth (n = 10,656) respectively (Budnitz 
et al., 2011).  Jha et al. (2001) identified hospital admissions due to adverse drug events using a 
computer-based monitor and found that among 3238 admissions, 76 (2.3%) were caused by an 
ADE, of which 78% were severe and 28% were preventable. Estimated costs were $16,177 per 
ADE, and $10,375 per preventable ADE; costs to the hospital were $6.3 million per year for all 
ADEs, and $1.2 million for the preventable ADEs.  
Phillips et al. (2008) reported an increase in the fatal medication error rate in the 
outpatient setting of 564 percent over the past 20 years.  Estimates are that ambulatory 
medication errors are expected to continue to increase exponentially with per-capita prescription 
use (Catlin, Cowan, Hartman, Heffler, & Team, 2008), and result in hospitalizations as 
Americans live longer, and have greater numbers of chronic conditions (Budnitz et al., 2011).  
Identification of potential correlates of medication discrepancies in the older primary care 
diabetic population may improve the process of medication reconciliation.  The results may lead 
to improved adherence, decreased medication error rate, and decrease ADEs.   
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 2.3 GAPS IN THE LITERATURE 
 
Based on the large number of studies regarding adherence and diabetes, more is known about 
adherence factors in the general primary care setting for persons with diabetes and much less 
about medication discrepancies specific to elderly patients with diabetes.  Among the medication 
discrepancy studies published in outpatient or primary care settings, limited patient, provider, or 
system characteristics were investigated; patient-specific medication discrepancy 
characterizations were absent in a review of the diabetic population literature.  
In prior studies of medication discrepancies in community dwelling adults, 
sociodemographic variables were limited to age and gender (Bedell et al., 2000; Orrico, 2008).  
Characteristics which may be implicated in predicting potential factors related to medication 
discrepancies include educational attainment, functional status, income level, employment status, 
insurance status, and social support; these were not investigated as potential correlates of 
medication discrepancies in prior studies.  Additionally, limited information was collected for 
provider or system characteristics, particularly the specialization of other prescribing providers, 
and provider actions when potential ADEs were identified.  While the type and number of 
comorbidities may affect the complexity of treatment regimens and have an impact on 
medication management, there was little to no information regarding the impact of comorbidities 
and associated sequelae on medication discrepancies specifically in the diabetic population.   
Comorbidities were not collected in other outpatient or primary care medication 
discrepancy studies (Bedell et al., 2000; Orrico, 2008) and the influence of comorbidities on 
medication discrepancies could not be assessed.  Studies which investigated depressive 
symptomology, subjective memory complaints, or cognitive function did not include an 
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 assessment of medication discrepancies in a single study of community dwelling elderly persons 
with diabetes over the age of 65 years. 
Therefore, gaps existed in the literature for the collection of structure variables that may 
affect the identification of potential descriptive correlates of medication discrepancies. The 
aforementioned limitation in prior research is particularly true in diabetic patients over the age of 
65 years who are seen in the primary care setting.   
This secondary data analysis captured many pertinent patient characteristics, including 
neuropsychological assessments, together with measures previously not explored in a single 
study to describe the sample. The quantity and quality of structure variables provided more 
complete information about potential correlates of medication discrepancies in diabetic persons 
greater than 65 years of age previously not documented from a single sample in the primary care 
setting. 
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 3.0  METHODS 
3.1 RESEARCH DESIGN 
3.1.1 Introduction 
This study was a secondary analysis of data prospectively collected at baseline during an 
experimental longitudinal trial that investigated the relationship between standard 
neuropsychological evaluation and patient outcomes in primary care. The current study was 
guided by the SPO model as set forth by Donabedian (1966, 1980, 1988) and used to guide 
health services research, quality improvement and patient safety research. See Figure 1 on page 5. 
The investigator was familiar with limited variables from the parent study; having 
exposure to some measures while assessing reliability and validity of a novel memory test. A 
secondary data analysis was an appropriate method for research because the parent study had 
data to address the questions surrounding medication reconciliation.  Additionally, the method 
diminished research expenditures, was time-efficient, eliminated recruitment and retention 
challenges, and participant burden was nonexistent.  
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 3.2  PARENT STUDY OVERVIEW 
The parent study, “Cognitive Assessment of Elderly Primary Care Patients,” was supported by a 
National Institute on Aging Grant 1R01 AG023129 (Principal Investigators: Judith Saxton, Ph.D. 
and Lisa Morrow, Ph.D.). The experimental longitudinal study sought to investigate the 
usefulness of cognitive testing (in primary care provider [PCP] offices) for clinical practice and 
clinical outcomes over a 2-year period.  
3.2.1 Parent Study Setting and Sample 
The study was conducted by investigators from the University of Pittsburgh.  Subjects were 
initially referred by their PCP in the greater Pittsburgh metropolitan area of southwestern 
Pennsylvania if they were aged 65 and older and did not have a medical chart diagnosis of 
dementia. The study took place from 2006 to 2010 and consented 533 patient subjects and 24 
PCPs; 423 subjects received a second neuropsychological assessment at 24-month follow-up.  
3.2.2  Parent Study Inclusion and Exclusion Criteria  
Parent study patient subjects were included for that study when subjects were aged 65 years and 
over and exhibited a Mini Mental State Exam (MMSE) score greater than 18.  Subjects were 
excluded if sensory deficits were present which would preclude cognitive testing (e.g., limited 
vision and hearing impaired). Subjects were also excluded if there was a documented diagnosis 
of dementia.  Neither reports nor observations of memory problems were exclusion criteria. The 
inclusion/exclusion criteria were inclusive regarding actual level of cognitive function (e.g., 
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 investigators expected some participants to score within the range of dementia on 
neuropsychological testing, given the low rates of dementia detection in PCP settings). In cases 
of a MMSE score of 18 or less, the study blind (randomized to neuropsychological feedback 
group or treatment as usual (TAU) was broken and the PCP was notified of the individual’s 
cognitive status.  All patient and physician participants provided written informed consent.   
3.2.3  Parent Study Procedures 
The patient subjects were asked to complete a series of paper and pencil tests and computerized 
memory tests that measured memory and other intellectual abilities. They also completed forms 
about their emotions and ability to conduct their usual activities. Interview, questionnaires, and a 
review of the medical record captured patient and provider characteristics, and medication-
related data. Patient subjects were rescreened with the same process and measures two years 
later.   
3.3  STUDY DESIGN 
3.3.1 Sample 
Inclusion/exclusion criteria for this secondary data analysis included only subjects with diabetes 
who were part of the 533 subjects enrolled in the parent study.   
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 3.3.2 Measures 
The current study was limited to structure and process variables collected during the baseline 
visit of the parent study. 
3.3.2.1  Structure Variables   
3.3.2.1.1 Sociodemographic factors 
Subject factors that were assessed included: sociodemographic variables, personal characteristic 
information, and neuropsychological status. Variables included age, gender, race, years of 
education, marital status, current employment status outside of the home (active in work force or 
retired), insurance status, social support or living arrangement, as well as standardized 
neuropsychological test scores.  
3.3.2.1.2 Personal characteristics 
Medication Management 
Medication management was assessed by responses to the structured interview from the 
“Medication Review” form. Responses to the following questions were captured: “How do you 
remember that it is time to take your pills?  How do you check that you have taken your pills?  
Of the meds that you are taking now, where do you get your prescriptions filled?  Do you have 
any problems paying for your medications?”   
Comorbidities 
Comorbidities were measured by the presence of a listed medical problem code as 
defined in the parent study, which were obtained from chart reviews by a study nurse at baseline 
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 and at six month intervals. The main categories were: psychiatric; neurological; heart; vascular; 
endocrine/metabolic; hematopoietic (blood, blood vessels, cells); respiratory (lungs, bronchi, 
trachea); eyes, ears, nose, throat (EENT); liver and renal; upper and lower gastrointestinal (GI); 
genitourinary; musculoskeletal / integument (muscles, bone, skin); and miscellaneous, which 
included medication issues. Each of the above categories had subcategories with specific codes.  
Polypharmacy 
Polypharmacy, the use of multiple medications or the administration of more medications 
than are clinically indicated (Hajjar, Cafiero, & Hanlon, 2007), was measured by the total 
number of unique medications the individual was taking as captured from the Chart Review, 2 
Years Prior to Baseline Testing, item 17C, “What are the current meds?”  
Sensory Changes 
Sensory changes were defined as self-reported auditory or visual impairments.  The 
Subject Demographics Form, item 14 captured visual impairment status by asking, “Do you wear 
eyeglasses or contact lenses?” followed by the fixed responses eyeglasses, contact lenses, both, 
or neither. Item 16 reads, “Can you see well enough to read newspaper print wearing corrective 
lenses?”  The fixed categorical responses were yes or no. Hearing impairment was captured from 
the categorical yes/no responses to item 15, “Have you ever worn a hearing aid?” and the 
categorical yes/no response to item 17, “Can you hear well enough to carry on a conversation in 
a quiet room?”  
Neuropsychological status 
Neuropsychological assessments included cognitive function across multiple domains for 
memory, learning, attention/psychomotor, spatial, and executive function.  Additional measures 
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 of subjective memory complaints, depressive symptomatology, and activities of daily living were 
obtained.   
Cognitive function 
Overall cognitive function was assessed by the score on the Mini-Mental State 
Examination (MMSE).  The MMSE is an instrument developed for grading the level of cognitive 
impairment of elderly patients in a clinical setting (Folstein et al., 1975). The MMSE has been 
used as a screening instrument for cognitive impairment associated with specific medical 
conditions (Mitchell, 2009; Munshi et al., 2006).  The MMSE is a 30-point scale consisting of 
individual tests of eleven domains: orientation (10 points); registration and recall (6 points); 
attention (5 points); multi-step command (3 points); two naming tasks (2 points); repetition task 
(1 point); reading comprehension (1 point); written sentence (1 point); and a visual construction 
task (1 point).  Internal consistency is reported as Cronbach’s alpha ranging from 0.54 to 0.96 
(Tombaugh & McIntyre, 1992) depending on the specific patient population. A practice effect 
was reported with repeat administrations (Galasko et al., 1997). Mitchell (2009) conducted a 
meta-analysis of 39 studies related to the accuracy of the MMSE in the detection of dementia and 
mild cognitive impairment (MCI) and reported modest accuracy with best value for ruling out a 
diagnosis of dementia in community and primary care. In the primary care setting the pooled 
sensitivity was 78.4%, specificity 87.8%, positive predictive value 53.6%, and negative 
predictive value 95.7%.  The MMSE in non-specialist settings was best at ruling out dementia, 
with approximately 29/30 correct reassurances and less than three false negatives out of every 
100 screens. 
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 Subjective Memory Complaints 
Subjective memory complaints in this study were measured by standardized questions 
developed to assess various aspects of subjective memory performance (Ganguli et al., 2004).  
The assessment includes general questions related to current functioning and change over the 
past year.  Respectively, these questions are “In general, how good do you feel your memory is 
for a person your age?” (scaled response is limited to “poor,” “fair,” “good,” and “excellent”) 
and “In general do you feel you remember things less well than you did a year ago?” (which 
received a categorical “yes/no” response).  
Depressive Symptoms   
Depressive symptoms in this study were measured by the modified version of the Center 
for Epidemiological Studies—Depression (mCES-D) Scale (Ganguli, Du, Dodge, Ratcliff, & 
Chang, 2006) (Ganguli et al., 1995).  The mCES-D differs from the CES-D in that it is 
interviewer-administered and asks the patients if symptoms are present (scored as 1) or absent 
(scored as 0) “most of the time” (defined as three or more days) during the preceding week. The 
maximum possible score is 20, with higher scores representing increased depressive symptoms.  
Ganguli et al. (2002) used a score of 5 on the 20-point scale as the cutoff point, as it defined the 
10% of their study cohort with the highest number of depressive symptoms in a sample of 1422 
participants aged 65 years and older in southwestern Pennsylvania.  The parent study of this 
secondary data analysis used a score of 4 on the 20-point scale because nearly everyone in the 
75th percentile reported at least 4 depressive symptoms (Fowler et al., 2012). 
Mild Cognitive Deficits and Pre-dementia Cognitive Changes  
All participants completed a neuropsychological test battery of 14 standard cognitive 
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 tests tapping multiple domains of memory, executive function, spatial ability, language, and 
attention/psychomotor speed.  The test battery was designed to detect mild cognitive deficits.  
Memory tests used were the Consortium to Establish a Registry for Alzheimer's Disease 
(CERAD) Word List Learning Test (WLL) (Morris et al., 1989) with delayed recall, the 
Wechsler Memory Scale- Revised (WMS-R) Logical Memory (LM) I and II  (D, 1987), and the 
modified Rey-Osterrieth (mR-O) figure immediate and delayed recall (Becker, Boller, Saxton, & 
McGonigle-Gibson, 1987). Executive function tests used included the Wechsler Adult 
Intelligence Scale-Revised (WAIS-R) Backward Digit span  (Wechsler, 1981), the controlled 
oral word association test (FAS) (Spreen & Strauss, 1998), the Clock Drawing Test (Spreen & 
Strauss, 1998), the Trail Making Test Part B (Reitan, 1958), and the WAIS-R Digit Symbol 
(Wechsler, 1981). Tests of spatial ability were the modified WAIS-R Block Design (Wechsler, 
1981) and the modified Rey-Osterrieth Copy (Shin et al., 2006). Tests of language abilities 
included the Boston Naming Test (Kaplan et al., 2001), letter fluency (number of letters starting 
with “F,” “A,” and “S” in 60 seconds each; FAS) and semantic fluency (animals) test (Spreen & 
Strauss, 1998). Tests of attention and psychomotor speed included WAIS-R Digit Span Forward 
25 and Trail Making Test Part A (Reitan, 1958), and Wechsler Adult Intelligence Scale-Revised 
(WAIS-R) Digit Span Forward (Wechsler, 1981).  
A total score of each domain was generated by obtaining a standardized z-score and 
summing tests within each domain. Additionally, a cognitive function total score was derived by 
adding all total scores across domains and dividing that score by five, which represented the total 
number of domains assessed. For this study, negative z-scores indicted worse performance when 
compared with the mean. The cognitive tests used in the parent study have reported validity and 
reliability statistics and have been used in older patient populations.  
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 3.3.2.2 Process Variable 
Medication Reconciliation 
Medication reconciliation was a comprehensive evaluative process for generating a complete and 
accurate list of a patient’s current medications and comparing the patient-generated list to those 
in the provider-generated list within the patient’s medical record. The provider-generated list for 
this study included the drug name and dose variables collected from item 17C on the Chart 
Review—2 Years Prior to Baseline Testing form, as the information was gleaned from the 
patient’s medical record. The patient-generated medication list was defined as the patient’s 
current medications and number of tablets or doses captured on the Medication Review form. 
The form documented responses during a structured medication review conducted by the parent 
study nurse in a brown bag interview with the participant. Documentation of medication 
information during the structured interview was taken from the bottles brought in for the 
appointment (participants were requested to bring all medications to the clinic in a bag), self-
report from the participant, or from a medication list provided by the patient. During the 
interview, the participant was asked a series of questions related to each medication on the 
patient-generated list: “Who prescribed this?” (responses were coded by medical specialty); 
“Why do you take this medication?”; “How much and how often do you take this medication?”; 
“Is this an over the counter medication?”; “Are you taking this medication as you are supposed 
to?” with follow up question “If no, why not?” Additionally, the participant was questioned as 
follows, “Are there any other medications that you take every day or only when you need them 
that you did not bring in today?” If so, those medications were added to the list.  
Medication discrepancies were measured by the presence or absence of concordance 
between the provider-generated list in the medical record and the patient-generated medication 
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 lists. The main outcome measure for this secondary data analysis was the presence or absence of 
medication discrepancies based on the medication reconciliation process of comparing the 
provider-generated list with the patient-generated list.  Any inconsistency discovered during the 
reconciliation process was classified as a medication discrepancy.  
When comparing the provider-generated list and the patient-generated list, a medication 
discrepancy was categorized as follows: 0-OK / in agreement (if total daily dose was the same); 
1-A medication the subject is taking that is NOT on the PCP list; 2-A medication the subject is 
NOT taking that is on the PCP list; 3-A difference in dosage (if a combined medication dose is 
wrong, code as discrepant); 4-A difference in schedule (if provider orders to take HS, patient 
must take QD or HS); 5-Data entry code for when items 3 and 4 are coded simultaneously; and 
6-Medication in agreement but dose and / or frequency is missing. Missing medication data was 
coded as -1 (see Appendix). 
3.4  DATA COLLECTION PROCEDURES 
Overview of the Data Collection Procedures 
Approval for an exempt study was obtained from the University of Pittsburgh Institutional 
Review Board (IRB).  IRB approval is included in the Appendix. Once IRB approval was 
obtained, the data manager for the parent study extracted and de-identified data prior to 
providing data files to this investigator for the secondary data analysis.  
The parent study collected data longitudinally at two time points, at baseline and at two 
years.  This secondary analysis utilized baseline data from the parent study collected between 
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 2006 and 2008. De-identified data for 533 subjects were provided electronically on an excel 
spreadsheet for ease in isolating specific variables under investigation during this secondary 
analysis. 
During a meeting with the parent study principal investigator and the data manager 
identified for this study, a review of the main parent study file (MPSF) revealed that specific 
variables of interest related to medications were not present in the file provided.   The variables 
of interest related to specific subjects and their specific medication data was subsequently 
located in a different electronic data file identified as parent study medication file (PSMF) and 
provided as de-identified data to this researcher.   
The architecture of the two data files provided was not conducive to a file merge.  The 
MPSF had one row per subject with variables labeled horizontally across the top of the sheet, as 
is customary. Variables in the PSMF were labeled in a horizontal method as is customary, 
however each subject had multiple rows based on the number of medications per subject. 
The MPSF and the PSMF both had variables for 533 subjects.  The MPSF was sorted by 
a diabetes problem code as the first step to identify diabetic subjects for this study.  The second 
step included a cross-validation and review of the PSMF to identify the prescribed medications 
each subject was taking for diabetes.  The final step in the determination of a diabetic subject 
was accomplished based on a review of the coded diabetes problem code in the MPSF and by a 
review of the data from the PSMF indicating a subject was taking a medication indicated for the 
treatment of diabetes and the patient’s self-report of diabetes as the rationale for taking the 
medication. Data were exported from the Excel files and merged into a common file for analysis 
using IBM®PASW® Statistics v.20.0 (Armonk, NY). Variables maintained the same coding as 
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 reflected in the parent study parent study codebook. The primary study file for this proposal was 
then generated which isolated diabetic subjects (n = 142) from the MPSF.    
In the PSMF, each subject had each type of medication discrepancy noted as absent or 
present by type of discrepancy for each medication documented; hence, there were multiple rows 
per subject. To accomplish a transfer of this information from the PSMF to the primary data file 
utilized for this secondary analysis, each medication discrepancy type (n = 6) was created as a 
single variable in the primary data file and coded for absence or presence across all medications 
associated with each unique subject. Therefore, the presence of a type of medication discrepancy 
by subject, regardless of the number of medications, was coded as a single variable for 142 
subjects.   
 
3.5  DATA SCREENING PROCEDURES 
Pre-Analysis Data Screening: Exploratory analysis was conducted to determine the final data set 
and sample size as described above. Preliminary data analysis included computation of means, 
modes, medians, frequencies, ranges of scores, standard deviations, and tests for normality and 
linearity. Scatterplots, histograms, and stem and leaf diagrams were created to visualize 
influential data points. Both parametric and nonparametric statistical procedures were utilized 
based upon the tests for normality. This included checking each of the variables for outliers by 
using scatterplots and stem and leaf diagrams. The degree to which the missing data may have 
been problematic was assessed by examining the pattern of the missing data within and across 
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 variables. Data transformations were performed as deemed necessary. In addition to evaluating 
descriptive statistics for data screening, correlations were examined and screened for 
multicollinearity in considering the possibility of data reduction. A correlation table was 
generated and analyzed to examine the correlation coefficients for each independent variable 
using the Pearson product-moment correlation and the Spearman rho. Collinearity statistics, 
including tolerance and the variance inflation factors (VIF), were examined.   
3.5.1 Missing data 
Multiple techniques were considered to address missing data. The pattern of missingness was 
assessed, random versus nonrandom, which included listwise and pairwise deletion.  
3.6  DATA MANAGEMENT AND ANALYSIS 
Sample size: The procedure for determining the sample involved an iterative process to 
merge data from the main parent study data file and the separate medication review data file for 
the parent study.  The following criteria had to be met prior to combining the data from the two 
data files into one singular data file with all the DM subjects represented.  The first criterion 
involved assessment of the main data file from the parent study (n = 533).  Based upon a 
documented diagnosis code for diabetes, data for 139 subjects were selected. The second 
criterion involved a cross-validation with the parent study medication data file.  A subject was 
included in the sample when one or more medications indicated for the treatment of DM were 
documented in the medication data file and the subject self-reported that the medication was 
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 prescribed for the treatment of DM.  The cross-validation yielded an additional three subjects.   
The sample size for the secondary data analysis was determined to be 142.  
3.7 ANALYSIS OF STUDY AIMS 
3.7.1 Primary Aim 1 
Characterize the sample of older community dwelling patients with DM.  
Descriptive statistics were analyzed to examine the characteristics of the sample. Means, 
standard deviations, and ranges were computed for all continuous variables.  Categorical 
variables were analyzed and presented as frequencies and percentages.  
3.7.2  Primary Aim 2 
Characterize the discrepancies associated with prescribed medications. 
Descriptive statistics were used to examine the presence and type of categorical medication 
discrepancy variables and were reported as frequencies and percentages.  
3.7.3 Primary Aim 3 
Identify potential correlates of medication discrepancies. 
Given that the dependent variable, medication discrepancy, was categorized as absent or present, 
logistic regression was the primary statistical approach used to assess the relationship between 
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 patient characteristics and medication discrepancy.  Univariate (bivariate) and multivariate 
logistic regression analyses were conducted to investigate which independent variables were 
significant predictors of the presence of medication discrepancy.  In the univariate analysis, each 
independent variable of interest was assessed separately as a potential correlate for the presence 
of a medication discrepancy.  The variables included age (in years), race (white or other races), 
education (in years), gender (male or female), marital status (married/living as married, 
widowed, or other), living situation (alone or with other), employment, number of unique health 
problem codes, and number of medications per patient.  Additionally, neuropsychological 
variables were assessed; these included MMSE, mCES-D, subjective memory complaints (yes or 
no), total scores from the five domains (memory, spatial, attention, language, and executive) 
measured in the neuropsychological battery of tests utilized to assess cognitive function, and a 
cognitive function total score.  The total scores for each domain in the cognitive function test 
battery were used for the analysis based on a high correlation of the individual tests within each 
domain (L. Morrow, personal communication, February, 10, 2014). Pearson product-moment 
correlation and Spearman’s rho correlation coefficients were examined and possible collinearity 
between independent variables was evaluated by collinearity statistics, i.e., tolerance and the 
variance inflation factors.  In the multivariate analysis, the combined effect of all the independent 
variables on the probability of medication discrepancy was investigated. Several multivariate 
logistic regression models were built to investigate how different subsets of the predictors 
affected the probability of medication discrepancy and to identify the best subset of predictors.  
Bivariate logistic regression analysis was conducted for each of the six types of 
medication discrepancy to determine what characteristics are associated with a specific type of 
medication discrepancy. This analysis provided evidence regarding the uniformity or the 
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 differences in type’s medication discrepancies.  
Results of the analyses include significance (p values), odds ratios, and the 95% 
confidence interval for odds ratios. The level of significance was set to be 0.05. The analyses 
were done using IBM®PASW® Statistics v.20.0 (Armonk, NY). 
3.8 PROTECTION OF HUMAN SUBJECTS 
This study was a secondary data analysis of existing data/documents/records collected at baseline 
from the parent study. The data were de-identified by the parent study data manager according to 
the Complete Health Insurance Portability and Accountability Act (HIPAA) of 1996.  This 
descriptive study met criteria for an exempt study with expedited approval by the University of 
Pittsburgh IRB in accordance with the Health and Human Services regulation in 45 CFR 
46.101(b)(4). The IRB approval and consent form appear in the Appendix. No potential risks 
existed to human subjects in this study as the data are not identified; the data that were provided 
were in compliance with HIPAA regulations. 
3.9 LIMITATIONS 
A secondary data analysis was conducted on a study that had been completed and utilized 
variables collected for a different research question.  There were inherent limitations when 
conducting this research using a secondary data analysis approach.  The researcher obtained 
approval from the principal investigator and ascertained data availability. Once the researcher 
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 provided documentation of IRB approval and specified the variables of interest, the parent 
study’s data manager was approached to obtain the data. A limitation of this secondary data 
analysis involved access to the data. The parent study had concluded and was no longer funded; 
hence the parent study research staff was no longer employed on the parent study. Partial files 
and data were housed on a computer not easily accessed by the honest broker.  Paper files were 
stored at an external facility; therefore, some data were unavailable.  
The honest broker for this secondary analysis had access to sufficient, but not all electronic 
data required for this secondary analysis. Data with limited or no access included the following: 
• Diabetes health problem code did not specify Type I versus Type II diabetes. 
• Neither sensory acuity nor insurance information was available in the electronic files 
provided. 
• Item responses were not available for the MMSE assessment. 
• Item responses were not available for the mCES-D.  
• Medication interview (qualitative response) data was not available in the electronic files 
provided. 
• There was a discordant formatting present on multiple data files due to the type of data (main 
data file and medication-related data file). Thus, no straightforward merge of the data files 
was possible. Data reduction was required and extrapolation from one type of file were 
required prior to the information being imported into SPSS format. 
In this secondary data analyses, the study population and measures collected during the 
parent study limited the type and scope of the proposed research. The variables available for 
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 analysis within the conceptual framework were limited to structure and process; therefore, it was 
not possible to include the outcome construct in the current study. The parent study was a 
longitudinal study, and some data collected later in the study was not available at baseline.  One 
example of data collected later in the study but not at baseline occurred during the medication 
interview process when the subject was questioned about the ability to pay for medications.  
Another example was the lack of biophysiologic measures, such as HgA1c, to assess glycemic 
control.   
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 4.0  RESULTS 
This study examined medication discrepancies in community dwelling adults with diabetes 
mellitus over the age of 65 years who were being followed by a primary care healthcare 
provider.  After an initial review of the data sampling procedures, this chapter provides the 
results of the three primary aims posited in chapter one: the characteristics of the sample; second, 
the characteristics of the medication discrepancies associated with prescribed medications; and 
third, identification of potential correlates of medication discrepancies. Because this was a 
secondary data analysis, the number of subjects with DM that met criteria for this analysis was 
not known a priori.  Therefore, the procedure and results of the inclusion criteria are outlined 
below.  All screening and analytic procedures were conducted in IBM®PASW® Statistics v.20.0 
(Armonk, NY) by the principal investigator. Missingness, outlier examination, and checking of 
statistical assumptions were performed prior to analysis. 
4.1 PROCEDURES 
4.1.1 Determining the Sample 
The procedure for determining the sample involved an iterative process to merge data from the 
main data file and the separate medication review data file of the parent study.  The following 
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 criteria had to be met prior to combining the data from two data files into one singular data file 
with all DM subjects represented.  The first criterion involved assessment of the main data file 
from the parent study (n = 533).  Based upon a documented diagnosis of DM, data for 139 
subjects were selected. The second criterion involved a cross-check with the medication data file.  
A subject was included in the sample when one or more medications prescribed for the treatment 
of DM were documented in the medication data file and the subject self-reported that the 
medication was prescribed for the treatment of DM.  The cross-validation yielded an additional 
three subjects for a total of 142 subjects with DM in the final data set. Baseline data in the 
primary study were collected between 2006 and 2010.  
4.2  DATA EXPLORATION STATISTICS 
Exploratory statistical analyses were conducted to screen for missingness, outliers, normality, 
collinearity, and homeoscedasticity. There was minimal missing data. Each of the five domains 
in the neuropsychological battery of tests had three randomly missing variables. Across all 
screenings, outliers were found for years of education, unique health problems, number of 
prescription medications, mCES-D, cognitive function total score and for each domain in the 
neuropsychological battery of tests for cognitive function. All neuropsychological variables were 
negatively skewed. Due to the sample size, nonlinearity, non-normal data distribution, and 
dichotomous dependent variables, bivariate and multivariate logistic regression were performed. 
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 4.3 PRIMARY AIMS 
4.3.1 Primary Aim 1  
Characterize the sample of older community dwelling patients with DM.  
During the preliminary data screening the selected subject characteristics were determined for 
the entire sample (see Tables 1–3).  Overall, there were a greater number of females than males 
(54.93% female; 45.07% male). There were significantly more participants who self-reported 
their race as white (93.66%).  Marital status assessment revealed 60.56% were married, 28.87% 
were widowed, 6.33% were divorced, and the remaining 4.23% were either never married or 
categorized as other. Sixty-nine percent of subjects reported living with someone, either a spouse 
or partner, or a relative or friend. Subjects who reported living alone comprised 29.58% of the 
study sample. Working outside of the home was reported by 21.83% (Table 1).  Health status, as 
a personal characteristic, revealed the presence of polypharmacy, comorbidities, and health 
problems. The range of scores on the mCES-D was 0–12 and n = 99 (69.72%) had scored greater 
than 4.  A score of 4 on the 20-point scale was used as the cutoff point for depressive 
symptomology because in the parent study nearly every subject in the 75th percentile reported at 
least four depressive symptoms. The mean number of health problems was reported as 9.94 (SD 
4.15); the prevalent comorbidities (active or past) and their percentage of the sample included:  
hypertension (86.62), hypercholesterolemia (83.10), and arthritis (62.68). Eight subjects had a 
note in the medical record indicating the presence of memory loss. (Table 2).  Mild cognitive 
impairment was identified in 44.37% of the sample.  Subjects with subjective memory 
complaints represented 10.56% of sample. The MMSE mean score was 27.94 with a range of 
21–30.   Mean scores across the domains (executive function, memory, spatial, language, 
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 attention/psychomotor) in the neuropsychological test battery were all below zero, negatively 
skewed, with two to nine outliers per domain. (Table 3). 
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 Table 1. Descriptive Statistics for Subject Personal Characteristics 
   Group 
Variable  Overall  
(N = 142) 
Discrepancy 
Present 
(N = 135) 
Discrepancy 
Absent 
(N = 7) 
Age, years* 
 73.32 (5.29)   73.39 (5.33) 72.08 (4.76) 
Education, years*  
13.46 (2.61)   15.00 (3.11)  13.38 (2.57)   
Sex**        
Female  78 (54.93) 75 (96.15) 3 (3.85) 
Male  64 (45.07) 60 (93.75) 4 (6.25) 
Race** 
White 
  
133 (93.66) 
 
126 (94.74) 7 (5.26) 
Other race  9 (6.34) 0 (.00) 9 (100.0) 
Marital status**       
Married  86 (60.57) 82 (95.35) 4 (4.65) 
Widowed  41 (28.87) 39 (95.12) 2 (4.88) 
Divorced  9 (6.34) 9 (100.00) 0 (.00) 
Never married  5 (3.52) 4 (80.00) 1 (20.00) 
Other  1 (.70) 1 (100.00) 0 (.00) 
Living situation     
Spouse/partner  87 (61.27) 83 (95.40) 4 (4.60) 
Alone  42 (29.58) 39 (92.86) 3 (7.14) 
Relative/friend  11 (7.74) 11 (100.00) 0 (.00) 
Other  2 (1.41) 2 (100.00) 0 (.00) 
Work outside home     
Yes  31 (21.83) 29 (93.55) 2 (6.45) 
No  111 (78.17) 106 (95.50) 5 (4.50) 
Note. *Standard deviations appear in parentheses with means.   
**Percentages appear in parentheses with counts.  
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Table 2.  Descriptive Statistics for Subject Health Status Characteristics 
   Group 
Variable  Overall  
(N = 142) 
Discrepancy 
Present 
(N = 135) 
Discrepancy 
Absent 
(N = 7) 
Mood*       
Modified CES-D     
< 4 depressive symptoms  43 (30.28%) 42 (97.67%) 1 (2.33%) 
≥ 4 depressive symptoms  99 (69.72%) 93 (93.94%) 6 (6.06%) 
Number of medications*  9.68 (4.56) 9.94 (4.51) 4.71 (1.70) 
Number of health problems*  9.94 (4.12) 9.88 (4.15) 11.14 (3.44) 
Hypertension **  123 (86.62) 116 (94.31) 7 (5.69) 
Hypercholesterolemia**  118 (83.10) 111 (94.07) 7 (5.93) 
Arthritis**  89 (62.68) 85 (95.51) 4 (4.49) 
Coronary Artery Disease**  55 (38.73) 54 (98.18) 1 (1.82) 
Cancer diagnosis**  36 (25.35) 35 (97.22) 1 (2.78) 
Chronic Obstructive 
Pulmonary 
Disease** 
 20 (14.08) 19 (95.00) 1 (5.00) 
Myocardial Infarction**  17 (11.97) 15 (88.24) 2 (11.76) 
Stroke**  17 (11.97) 17 (100.00) 0 (.00) 
Memory loss**  8 (5.63) 8 (100.00) 0 (.00) 
Note. *Standard deviations appear in parentheses beside means.   
**Percentages appear in parentheses beside counts. 
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 Table 3.  Descriptive Statistics for Subject Neuropsychological Status Characteristic Measures 
   Group 
Variable     Overall 
(N = 142) 
 
Discrepancy 
Present 
(N = 135) 
Discrepancy 
Absent 
(N = 7) 
Cognitive Status     
Normal cognition*  73 (51.40) 67 (91.78) 6 (8.22) 
Mild Cognitive Impairment*  63 (44.37) 62 (98.41) 1 (1.59) 
Dementia*  6 (4.23) 6 (100.00) 0 (.00) 
Subjective memory complaints     
Yes*  20 (14.08) 20 (100.00) 0 (.00) 
No*  122 (85.92)   122 (85.92)    0 (.00) 
MMSE score**    27.91(1.83)         27.87(1.84)   28.57 (1.62) 
Cognitive function total      
score** 
   
 -.90 (.82) -.94 (.83) -.32 (.47) 
Executive function  -.83 (1.02) -.87 (1.03) -.16 (.32) 
Memory  -.98 (.96) -1.00 (.97) -.48 (.67) 
Spatial  -.97 (.96) -.99 (1.18) -.69 (.62) 
Language  -1.03(1.30) -1.07 (1.31) -.16 (.46) 
Attention/psychomotor  -.61 (1.07) -.64 (1.14) .03 (.94) 
 Note. *Percentages appear in parentheses beside counts.  **Standard deviations appear in 
parentheses beside means. 
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Associations among the Patient Characteristics  
Given that the data were non-normally distributed, Spearman’s rho correlation coefficient was 
used.  The standardized skewness coefficients for the MMSE and the five neuropsychological 
domains (represented by the global cognitive function score) justified the choice for utilizing the 
Spearman’s rho correlation coefficient. The Spearman’s rho correlation coefficient revealed a 
statistically significant relationship between cognitive function total score and the individual 
domains, which were components of the cognitive function total score. Additionally, the 
Spearman’s rho revealed a statistically significant negative relationship between age and MMSE 
and the global cognitive function score.  A significant positive relationship was noted between 
education and the MMSE and the global function cognitive score. Moreover, a significant 
positive relationship was present for the number of medications with the number of health 
problems. The number of health problems had a significant negative correlation with the memory 
domain and the global cognitive function score but not with other domains. MMSE was 
significant for positive correlations across all cognitive domains. Squaring the correlation 
coefficients indicated that the variances between the above differences minimally explained the 
relationships. The correlation matrix is presented in Table 4. 
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 Table 4. Associations Among Measures of Subject Characteristics, Health Status, and Neuropsychological Variables 
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4.3.2 Primary Aim 2   
Characterize the discrepancies associated with prescribed medications. 
Medication discrepancy was evident in n =135 (95.07%) of subjects.  The seven subjects without 
a medication discrepancy were not prescribed nor were they taking a medication to treat DM.  
Presence of self-reported medication discrepancies was categorized as:  
• taking but not documented in the provider’s list of medications;  
• not taking yet documented in the provider’s list of medications;  
• combined dose is different than the combined dose documented in the provider’s 
list of medications;  
• administration time is different than the provider’s list of medications;  
• medication dose and schedule is different from the provider’s list of medications; 
and lastly,  
• a given medication is congruent with the provider’s list but the dose and/or the 
frequency is missing.  
Table 5 presents the type of discrepancy for all medications and the frequency.   
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Table 5.  Medication Discrepancy Types and Frequencies (n = 135) 
Type of discrepancy as assessed through patient self-report N (%) 
Taking medications that were not documented in the provider’s list of 
medications 
93 (68.89) 
Not taking a medication that was documented in the provider’s list of 
medications 
0 (0%) 
Combined dose was different than the combined dose documented in 
the provider’s list of medications 
55 (40.74) 
The administration time was different than the provider’s list of 
medications 
43 (31.85) 
Medication dose and schedule was different from the provider’s list of 
medications 
21 (15.56) 
Medication was congruent with the provider’s list but the dose and/or 
the frequency was missing 
89 (65.93) 
Note. *Percentages appear in parentheses.  
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4.3.3 Primary Aim 3 
Identify potential correlates of medication discrepancies. 
Univariate logistic regression revealed that the number of recorded medications was the only 
significant predictor of medication discrepancies (p = .003). For each additional medication, the 
odds of medication discrepancy increased by about 59% (OR = 1.59, 95% CI [1.17, 2.15]).  
There was a trend evident for diminished cognitive function as measured by the cognitive 
function total score and the presence of medication discrepancies (p = .053)  (Table 6).   
 
Table 6.  Univariate Logistic Regression Results for Presence of Medication Discrepancy 
 
Variable 
 95% CI for Odds Ratio 
P value Odds Ratio Lower Upper 
Age  .52 1.05 .90 1.23 
Race, white vs. other races 1.00 NC NC NC 
Education, in years .12 .81 .62 1.06 
Gender, male vs. female .51 .60 .13 2.79 
Marital status, married vs. other .74 1.46 .15 14.08 
                        widowed vs. other .79 1.39 .12 16.58 
Living situation, alone vs. with other .44 .54 .12 2.53 
Employed, yes vs. no .66 .68 .13 3.71 
Number of health problems  .42 .94 .80 1.10 
Number of medications .003* 1.59 1.17 2.15 
MMSE .35 .78 .47 1.31 
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 mCES-D score ≥ 4 vs. < 4 .363 .369 .043 3.162 
MCI vs. normal .117 5.55 .650 47.43 
Subjective memory complaints, yes 
vs. no 
1.00 NC NC NC 
Cognitive function, memory  .16 .52 .21 1.30 
                                 Spatial .52 .78 .37 4.65 
                                 Attention .10 .40 .13 1.19 
                                 Language .07 .41 .16 1.06 
                                 Executive .054 .29 .08 1.02 
Cognitive function total score .053 .23 .52 1.02 
Note. NC = not calculated due to zero counts for some categories. * Significant at the 0.05 
level (2-tailed). 
 
 
In the multivariate analysis, race, marital status, living situation, and subjective memory 
complaints were excluded due to the low or zero counts in some of the variables’ categories. 
Cognitive function total score was also excluded since it was a combination of the five domains’ 
scores of the cognitive function. The combined effect of age (in years), education (in years), 
gender (male or female), employment, number of unique health problems, number of 
medications per patient, MMSE, mCES-D, and scores from the five domains (memory, spatial, 
attention, language, and executive) measured in the neuropsychological battery of tests utilized 
to assess cognitive function was investigated. The findings showed that the number of 
medications (p = .025) and the number of unique health problems (p = .011) were significant in 
predicting the probability of medication discrepancy. For every additional medication, the odds 
of medication discrepancy increased by 118% (OR = 2.18, 95% CI [1.20, 3.95]), while all the 
other variables in the model were held constant. For every additional health problem, the odds of 
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 medication discrepancy decreased by 33% (OR = .67, 95% CI [.47, .95]), while all the other 
variables in the model were held constant. Table 7 presents the results of the multivariate logistic 
regression for all the independent variables considered in the model to predict the probability of 
medication discrepancy (model 1). 
 
Table 7.  Model 1.  Multivariate Logistic Regression Results for Presence of Medication Discrepancy 
 
Variable 
 95% CI for Odds Ratio 
P value Odds Ratio Lower Upper 
Age  .94 .99 .71 1.38 
Education, in years .14 .69 .42 1.13 
Gender, male vs. female .81 1.48 .06 36.70 
Employed, yes vs. no .99 .98 .07 14.18 
Number of medications  .01* 2.18 1.20 3.95 
Number of health problems .03* .67 .47 .95 
MMSE .41 1.38 .65 2.92 
mCES-D .40 1.22 .77 1.93 
Cognitive function, memory  .33 .33 .03 3.16 
                                   Spatial .48 2.34 .23 24.22 
                                   Attention .40 .47 .08 2.77 
                                   Language .28 .42 .09 2.04 
                                   Executive .91 1.14 .12 10.89 
Note. * Significant at the 0.05 level (2-tailed). 
 
The number of medications and the number of health problems remain significant 
predictors when they were entered in the model along with age, education, gender, and cognitive 
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 function total score only (model 2, Table 8) or along with age, education, gender, and the five 
domains of the cognitive function (model 3, Table 9). The magnitude of the effects of the 
significant predictors estimated with models 2 and 3 were OR = 1.97, and OR = 2.01, 
respectively, for the number of medications, and OR = .73, and OR = .71 for the number of 
health problems. 
 
 
 
Table 8.  Model 2. Multivariate Logistic Regression Results for Presence of Medication Discrepancy 
  
 Variable 
  95% CI for Odds Ratio 
 P value Odds Ratio Lower Upper 
 Age  .92 1.01 .80 1.29 
 Education, in years .19 .74 .47 1.17 
 Gender, male vs. female .67 1.66 .18 15.13 
 Number of medications  .007* 1.97 1.21 3.20 
 Number of health problems .03* .73 .55 .97 
 Cognitive function, memory  .27 .31 .04 2.43 
 Constant .59 71.06   
 Note. * Significant at the 0.05 level (2-tailed). 
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Table 9.  Model 3.  Multivariate Logistic Regression Results for Presence of Medication Discrepancy 
  
 Variable 
  95% CI for Odds Ratio 
 P value  Odds Ratio Lower Upper 
 Age  .90 .98 .74 1.30 
 Education, in years .17 .73 .46 1.15 
Gender, male vs. female .95 .92 .06 15.03 
 Number of medications  .01* 2.01 1.22 3.32 
 Number of health problems .03* .71 .52 .97 
 Cognitive function, memory  .31 .35 .05 2.62 
Spatial .25 3.26 .43 24.88 
Attention .54 .60 .12 3.04 
 Language .35 .52 .13 2.04 
 Executive .84 .81 .11 5.97 
 Constant .45 1408.1   
Note. * Significant at the 0.05 level (2-tailed). 
 
Since only the number of medications and the number of health problems were 
significant predictors, the best model of predicting the probability of medication discrepancy is 
the model having these two predictors. The results of this model (model 4) are presented in table 
10.  For every additional medication, the odds of medication discrepancy increased by 94% (OR 
= 1.94, 95% CI [1.28, 2.94]), while the number of health problems was held constant. For every 
additional health problem, the odds of medication discrepancy decreased by 38% (OR = .72, 
95% CI [.55, .94]), while all the other variables in the model were held constant.  Figure 3 shows 
the predicted probability of medication discrepancy by number of medications, when number of 
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 health problems is 5, 10, and 15 respectively. As the number of medications increases, the 
probability of medication discrepancy increases for all three categories of health problems. 
Subjects with 15 health problems had lower probability of medical discrepancy compared to the 
group with five or 10 medical problems. For subjects with more than 10 medications, it was 
estimated that they are likely to have medication discrepancy regardless of the number of health 
problems (probability close or equal to 1). 
 
Table 10.  Model 4. Significant Predictors for Presence of a Medication Discrepancy 
 
Variable 
 95% CI for Odds Ratio 
P value Odds Ratio Lower Upper 
Number of medications .002* 1.94 1.28 2.94 
Number of health problems  .02* .72 .55 .94 
Note. * Significant at the 0.05 level (2-tailed).     
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Figure 3. Predicted Probability of Medication Discrepancy 
 
Each type of medication discrepancy was investigated for potential correlates with 
subject characteristics. Of the 135 subjects with a medication discrepancy, 93 (69%) had the 
medication discrepancy of taking but not documented in the provider’s list of medications, none 
had medication discrepancy of not taking yet documented in the provider’s list of medications, 
55 (41%) had the medication discrepancy combined dose is different than the combined dose 
documented in the provider’s list of medications, 43 (32%) had the medication discrepancy 
combined dose is different than the combined dose documented in the provider’s list of 
medications, 21 (16%) had medication discrepancy administration time is different than the 
provider’s list of medications, and 89 (66%) had medication discrepancy  an given medication is 
congruent with the provider’s list but the dose and/or the frequency is missing. 
The significant findings are described below.   
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 The medication discrepancy of taking but not documented in the provider’s list of 
medications revealed the following significant patient characteristics. The number of 
medications in the subject’s armamentarium (p =.002), and the number of unique health 
problems (p = .018) were significant predictors. For each additional medication, the odds of 
medication discrepancy of taking but not documented in the provider’s list of medications 
compared to all the other types increased by about 18% (OR = 1.18, 95% CI [1.06, 1.31]). For 
each additional health problem, the odds of medication discrepancy of taking but not documented 
in the provider’s list of medications increased by 14% (OR = 1.14, 95% CI [1.02, 1.27]).     
The medication discrepancy combined dose is different than the combined dose 
documented in the provider’s list of medications was associated with the number of medications 
(p = .005) and the number of health problems (p = .027). For each additional medication, the 
odds of medication discrepancy combined dose is different than the combined dose documented 
in the provider’s list of medications increased by 13% (OR = 1.13, 95% CI [1.04, 1.23]). For 
each additional health problem, the odds of medication discrepancy combined dose is different 
than the combined dose documented in the provider’s list of medications increased by about 11% 
(OR = 1.11, 95% CI [1.01, 1.21]).     
  The medication discrepancy administration time is different than the provider’s list of 
medications was associated with the number of medications (p = .041). For each additional 
medication, the odds of medication discrepancy administration time is different than the 
provider’s list of medications increased by 9% (OR = 1.09, 95% CI [1.003, 1.18]). 
Examining the medication discrepancy medication dose and schedule is different from 
the provider’s list of medications, the number of medications was not significant for this specific 
discrepancy (p = .105), nor the number of health problems (p = .174). 
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 The medication discrepancy a given medication is congruent with the provider’s list but 
the dose and/or the frequency is missing was associated with the number of medications (p = 
.029). For each additional medication, the odds of medication discrepancy a given medication is 
congruent with the provider’s list but the dose and/or the frequency is missing increased by 11% 
(OR=1.11, 95% CI [1.01, 1.21]). 
The results presented above indicate that medication discrepancies are present in persons 
with diabetes in the primary care setting and increase based on the number of health problems.  
A summary and discussion of the findings are presented in the next chapter.   
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 5.0  DISCUSSION, CONCLUSIONS, AND IMPLICATIONS 
This study focused on patient factors, particularly cognitive function, that to date have not been 
investigated in any study of medication reconciliation specifically in a diabetic patient 
population. Donabedian’s structure-process-outcome model guided the aims for this secondary 
analysis. The study was descriptive and cross-sectional using baseline data from an experimental 
longitudinal trial to address structure and process variables.  Outcome measures were not 
examined in this secondary data analysis.  As such, this study did not assess the impact of 
medication discrepancy on patients’ outcomes.  Thus, it is not known if the medication 
discrepancies had a negative impact on patient outcomes and resulted in adverse events. This 
chapter reviews and discusses the main findings of this dissertation, describes the implications 
this work has for future research, and identifies limitations of the study. 
5.1 SUMMARY OF THE STUDY 
The purpose of this secondary data analysis was to examine subject characteristics and 
medication discrepancies associated with DM in adults 65 years of age and older who were 
community dwelling primary care patients and to determine if potential correlates existed 
between and among patient characteristics and medication discrepancies.  
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 This secondary analysis used de-identified baseline data from a parent study (n = 533) 
that investigated the usefulness of cognitive testing in a primary care setting. The parent study 
baseline data collection occurred from 2006 into 2008. Exempt approval was obtained from the 
University of Pittsburgh Institutional Review Board (IRB) for a retrospective secondary analysis 
(IRB # PRO14010425, see Appendix).   Data from two architecturally distinct databases from 
different software programs (Excel and SPSS) were combined in order to determine the sample 
of subjects with diabetes and conduct this secondary data analysis. The sample for this analysis 
was determined to be 142 subjects with DM.   
5.2 SUMMARY OF THE FINDINGS 
This study found that 95.07% of subjects displayed evidence of at least one medication 
discrepancy, indicating that there are a considerable number of community dwelling persons 
with diabetes 65 years of age and older who are being seen in a primary care setting and who 
have a medication discrepancy.  All prescription medications were reviewed in determining the 
medication discrepancies. The different types of discrepancies measured were reflective of 
comparisons between the primary care medical record and a brown bag review of the subject’s 
medications obtained at the baseline study visit.  The types of discrepancies included: taking or 
not taking a medication that was evident in the medical record, dosing discrepancies, and 
schedule of administration discrepancies.  The extent of medication discrepancies in this study 
was higher than the 30%–76% previously reported in outpatient studies (Barat et al., 2001; 
Bloom et al., 1993; Coleman et al., 2005; Gleason et al., 2004; Gonski et al., 1993; McKinley et 
al., 2004; Moore et al., 2003).  This difference may have been related to the sample being limited 
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 to persons with diabetes and the meticulous brown bag review and documentation by study 
personnel.  Consistent with findings of Bedell and colleagues (2000), the probability of having a 
medication discrepancy was positively related to the total number of medications taken by the 
subject.  
Much of the existing literature on medication use and misuse in older persons with 
diabetes focused on subject adherence, which assessed the failure of subjects to adhere to 
prescribed medications.  The differences between the definitions of nonadherence and 
discrepancy notwithstanding, existing data on high rates of nonadherence in the DM population 
(Odegard and Capoccia, 2007; Field et al., 2007) are consistent with the present findings.  This 
finding is in conflict with Grant et al., (2003) who reported high medication adherence rates and 
high prevalence of medication discrepancies, which appeared to reflect medication inaccuracies 
in the medical record rather than subject errors.  
A unique aspect of this study includes assessment of cognitive function in a study of 
medication discrepancies involving DM patients. Many studies have evaluated cognitive 
function in the DM population, but none have assessed cognitive function as a potential predictor 
of medication discrepancies.  
5.2.1 Specific Aim Findings 
Aim 1.  Characterize the sample of older community dwelling subjects with DM 
Subject characteristics in this sample of older community dwelling persons with diabetes were 
described as structural constructs within the Donabedian model.  This study included older (65 to 
88 years of age) subjects with the majority being women. While not a significant predictor of 
medication discrepancy in this study, all subjects were above 65 years of age, which was 
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 consistently cited as a factor related to medication discrepancies (Bedell et al., 2000; Gilbert et 
al., 1993).  
The mean years of education was approximately 13, with a quarter of the subjects having 
greater than 12 years of education, and approximately half of those with more than 16 years of 
education, indicative of a highly educated sample for this study. Education has been cited as 
being a protective factor for cognitive decline; this may also have influenced the high MMSE 
scores in this study. There was a positive correlation for years of education and MMSE, memory, 
attention, language, and executive function, despite the lower mean scores in the 
neuropsychological battery of tests. MMSE scores overall were high, as represented by a mean 
score of about 28.  This finding was expected, as individuals with dementia were excluded from 
the study.  High MMSE scores were also evident in previous secondary analysis studies utilizing 
the same parent study (Fowler et al., 2012; Morrow et al., 2009; Snitz et al., 2008). As postulated 
in prior studies, this finding was due to the exclusion of potential participants with a diagnosis of 
dementia documented in the medical record. 
Polypharmacy was evident with a subject having, on average, about 10 medications 
prescribed. A quarter of the subjects took more than 12 medications. This finding supported 
earlier studies, which identified polypharmacy (Grant et al., 2003b; Coleman et al., 2005; Caskie 
et al., 2006) as a variable or factor contributing to medication discrepancy errors.  Polypharmacy 
was significantly correlated with the number of health problems; the higher the number of 
medications, the higher number of health problems. 
The negative mean scores in the neuropsychological battery of tests, could be reflective 
of this DM sample, in addition to almost 45% of the subjects having mild cognitive impairment, 
which is slightly higher than the total parent study sample (n = 533).  Ryan (2005) reported 
cognitive domains most frequently impaired in persons with diabetes were memory, attention, 
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 psychomotor speed, and problem solving; which was supported by the findings from this study. 
The mean scores for this DM cohort were lower than the overall parent study sample indicating 
an increased prevalence of cognitive impairment in DM subjects. The global cognitive function 
score was reflective of cognition as a whole and included all domains measured (memory, 
spatial, attention, language, and executive function). The global cognitive function score was 
significant for negative correlations with age, and the number of health problems: and was 
significant for positive correlations with education and MMSE.  Significant negative correlations 
were noted for memory and number of health problems; the number of medications was 
negatively correlated with the attention domain. Therefore, cognitive function, overall, was 
associated with age, education, number of health problems, and number of medications.  
There were several unmodifiable characteristics of the sample, which are limitations.  
Subjects were recruited from southwestern Pennsylvania as participants for a larger study of 
cognitive function screening in primary care.  The subjects were initially selected based on 
primary care providers also serving as study participants for determination of provider 
characteristics for the parent study. Therefore, because providers were also participants in the 
parent study, there may have been a bias in the sample. All patient subjects had health insurance 
coverage, as the lower age for inclusion was 65 years; yet, the source and type of health care 
coverage was not known.  The percent of non-whites in the study was half of that estimated by 
the U.S. Census for the region, and was not representative of the general population in 
southwestern Pennsylvania.  The provisional diagnosis of diabetes was based on a combination 
of self-report and objective medication data. It was not possible to determine Type I or Type II 
DM.  Results from this sample may not necessarily be representative of an aging population 
based on race, education, and cognitive function level.  
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 The measures used in this secondary analysis were those available from data files of the 
parent study. A potential limitation to this study was that the majority of the data was self-
reported.  However, the self-report data was confirmed through the medical record review in the 
parent study. Biological information, such as an HbA1c level, reflective of glycemic control, 
were not available in a sufficient number of subjects to be used as a potential correlate for 
medication discrepancies nor for the neuropsychological tests of cognitive function. Prior studies 
have associated inadequately controlled diabetes and declining cognitive function in older adults 
(Cukierman-Yaffe et al., 2009; Grober et al., 2011). Therefore, having  a biophysiologic variable, 
such as HbA1c to measure diabetes control may have helped to explain this study’s findings.  
Analysis of the neuropsychological variables revealed negative z-scores across all 
domains in this diabetic sample. Negative scores indicated a worse performance when compared 
with the mean.  Because these z-scores were compared with the mean from the parent study 
(Fowler et al., 2009), it was not possible to back-transform these scores specifically for this study 
in diabetic subjects nor to assess individual test results within a given domain of cognitive 
function.  
 
Aim 2. Characterize the discrepancies associated with prescribed medications 
When examining the medication discrepancies of the 142 subjects in this study, 95% of 
them had evidence of at least one medication discrepancy. This number is higher than the 76% 
reported by Bedell et al. (2000) in an outpatient study.    
The types of medication discrepancies ranked by highest frequency included: taking 
medications that were not documented in the provider’s list of medications (70%); medication 
that was congruent with the provider’s list but the dose and/or the frequency was missing (67%); 
combined dose was different than the combined dose documented in the provider’s list of 
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 medications (42%); the administration time was different than the provider’s list of medications 
(33%); medication dose and schedule was different from the provider’s list of medications 
(16%).  Taking yet not documented in the provider’s list of medications as a discrepancy was not 
coded as being present in the medication data file for any patient.  
The discrepancy taking medications that were not documented in the provider’s list of 
medications was evident in 70% of subjects in this study. In other outpatient studies subjects 
taking medications that were not recorded was evident in 50% (Bedell et al., 2000) and 87% 
(Miller et al., 1992). One possibility for the lower percentage in Bedell et al. (2000) could be due 
to the research being limited to its own practice and not across multiple practices. The present 
study drew subjects from eleven different primary care practices.  Additionally, the number of 
prescribing providers for subjects in this study likely extended to specialists in addition to the 
primary care provider due to the high number of reported health problems. A direct relationship 
was identified between the number of prescribing providers and the presence of medication 
discrepancies (Bedell et al., 2000; Malhotra et al., 2001; Tamblyn et al, 1996; and Tulner et al., 
2009).  
The discrepancy capturing differences in dosage was higher in the Bedell (2000) study 
(20%), compared to 16% for this study. The present study did capture instances where a limited 
number of subjects reported that the provider verbally communicated a medication dose 
modification.  This communication may have been a reason for the dose discrepancy, as the 
medication bottle label would not have reflected this verbal communication. 
 
Aim 3. Identify potential correlates of medication discrepancies. 
Once medication discrepancies were identified as present in 135 subjects and absent in 
seven subjects, the sample was grouped accordingly.  Sociodemographic covariates were not 
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 predictive of medication discrepancies, whereas health status covariates, represented by the 
number of medications and the number of health problems, were predictive of medication 
discrepancies. While not significant, there was a trend for diminished cognitive function as 
evidenced by the cognitive function total score and the presence of a medication discrepancy. 
The effects of diabetes on neuropsychological function have been reported in the literature 
(Luchsinger et al., 2011; Kodl and Seaquist, 2008); yet, no investigations reported assessment of 
specific domains of cognitive function in a study of medication discrepancies. Rosen et al. 
(2003) reported a modest nonspecific association between metformin adherence and 
neuropsychological function. This study was not designed to analyze specific test results 
administered within individual neuropsychological domains, as the individual tests were not 
available for analysis. Therefore, the findings related to neuropsychological tests were limited by 
mean domain scores rather than by individual tests conducted within each domain.  
Health status variables were predictive of medication discrepancies. The number of 
medications was significant in predicting the probability of medication discrepancy in addition to 
the number of health problems. This finding supports earlier studies that identified polypharmacy 
(Grant et al., 2003b; Coleman et al., 2005; Caskie et al., 2006) as a variable or factor contributing 
to medication discrepancy errors. While multiple health problems were contributing factors for 
the increased number of prescribed medications in the DM population (Caughey et al., 2010; 
Good, 2002; Odegard & Capoccia, 2007), medication discrepancies related to multiple health 
problems were not identified in the literature.   
Among subjects with the same number of health problems, those with a higher number of 
medications were more likely to experience a medication discrepancy compared to the subjects 
with a lower number of medications. Among subjects with the same number of medications, 
those with a higher number of health problems were less likely to experience a medication 
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 discrepancy compared to the subjects with a lower number of health problems.  This novel 
finding was of particular interest as it had not been described elsewhere in the medication 
discrepancy literature.  
Each type of medication discrepancy was investigated for potential correlates with 
subject characteristics.  The predominant predictors for each type of discrepancy were the 
number of medications and the number of health problems.  However, these were not predictive 
of the medication discrepancy medication dose and schedule is different from the provider’s list 
of medications.    
 
The present study found that the number of health problems was associated with different 
types of medication discrepancies.  This relationship may be supported in the literature where the 
number of comorbid conditions has been associated with poorer cognitive function (Morrow et 
al., 2009).  A higher disease burden places one at greater risk for poorer cognitive functioning 
(Patrick et al., 2002; Proctor et al., 2003), and possibly decreases the ability of patients to self-
manage their diabetes (Halanych et al., 2007; Kerr et al., 2007). However, the present study 
found that subjects with a higher number of health problems were less likely to have a 
medication discrepancy compared to the subjects with a lower number of health problems when 
taking the same number of medications.  Possibly, subjects realized that increased self-
management was warranted due to increasing health problems.  
The cognitive function total score was not a predictor of medication discrepancy in this 
study, but a trend was suggested by the study findings.   This nonsignificant finding of a decrease 
in cognitive function may have influenced but did not predict the presence of medication 
discrepancies. It was not possible to discern errors of omission or commission, intentional versus 
nonintentional, or subject versus provider responsibility, for individual medication discrepancies.  
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 5.3 CONCLUSIONS 
This study contributed to the literature by describing specific types of medication discrepancies 
and the covariates in an older community dwelling population of persons with diabetes in a 
primary care setting in which almost half of the subjects were found to have cognitive 
impairment, a large number of health problems, and were prescribed a large number of 
medications. Ninety-five percent of the subjects had a least one medication discrepancy.  This 
was a higher percentage than previously reported in the literature, and may have been due to the 
specific sample of older DM subjects. 
The results of this study revealed that among subjects with the same number of health 
problems, those with higher number of medications were more likely to have a medication 
discrepancy compared to the subjects with a lower number of medications. Among subjects with 
the same number of medications, those with a higher number of health problems were less likely 
to have a medication discrepancy compared to the subjects with a lower number of health 
problems. 
The pervasiveness of medication discrepancies and health problems in this older 
population of persons with diabetes may have significant health care implications that deserve 
further study, particularly with a trend noted for diminished cognitive function.  The results 
qualify and extend implications of previous medication discrepancy studies. 
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 5.4 IMPLICATIONS 
Over the past decade, medication reconciliation became policy-driven and was a vital component 
of the health care process across all trajectories of care to promote patient safety by decreasing 
medication errors (Kocher, Emanuel, & DeParle, 2010). The U.S. Congress passed the Medicare 
Post-Acute Care Transformation Act of 2014 (IMPACT Act) (H.R. 4994/S. 2553) in September 
2014, which was signed by the President of the United States and enacted in October 2014.  The 
act will require, among other actions, the assessment of quality measures for medication 
reconciliation and cognitive function and will take effect in 2017 and 2019, respectively. The 
IMPACT Act will provide a mechanism for reimbursement for cognitive screening at geriatric 
well visits.  To collect data for these quality measures discovered during the medication 
reconciliation process, it will be prudent to include variables, which have been shown to be 
potential structure and process predictors of medication discrepancies.  
Findings from this research may contribute to modifications in geriatric curriculum 
development in the education of nursing students.  Nurses who serve an elderly patient 
population need to assess patient’s knowledge, understanding, and management of their 
medications to prevent adverse drug events and promote improved patient outcomes.  The 
findings may also suggest further nursing research to understand the precise cognitive function 
deficits and the impact on medication discrepancies in an older community dwelling diabetic 
population.  Future studies are warranted to examine longitudinal trends in medication 
discrepancies vis-à-vis the medication reconciliation process among older persons with diabetes. 
Future research should include assessments of health literacy in a racially and culturally diverse 
sample. Measurement of adherence and medication discrepancies should occur simultaneously 
and include biological measures, such as HbA1c, to assess glycemic control in persons with 
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 diabetes. Future research should also focus on identification of the best neuropsychological 
assessment feasible in the primary care setting in order to determine whether different types and 
patterns of cognitive decline occur over time, which may subsequently affect medication 
management, and hence the control of diabetic symptoms.    
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